The FDA issued an advisory August 7 updating healthcare providers and the public on its stance regarding the long-term safety of paclitaxel-coated and -eluting devices, sharing that its expert panel had indeed identified a late mortality signal associated with the devices.

TARA Biosystems’ “heart-on-a-chip” system successfully replicates human drug responses to CV medications without having to risk cardiotoxicity in human testing, researchers from TARA and GlaxoSmithKline announced August 6.

People with osteoarthritis are 23% more likely to develop CVD than their non-arthritic counterparts if they regularly use NSAIDs, according to research published in Arthritis & Rheumatology August 6.

A systematic review analyzing the cardiovascular impact of nearly two dozen armed conflicts has identified a link between war and an increased incidence of coronary heart disease, cerebrovascular and endocrine diseases, and other risk factors among civilians.

A federal review of UNC Hospital’s pediatric cardiology unit found “no current deficiencies” in the program just two months after the New York Times published an article suggesting the unit was in “total disarray."

A study out of Brigham and Women’s Hospital in Boston has found patients insured through TRICARE, the U.S. military’s universal health insurance program, saw similar CABG outcomes regardless of their race.

Overall exposure to ionizing radiation for patients undergoing radiofrequency ablation of AFib is “acceptable” in most cases, according to research published in the American Journal of Cardiology—but obese patients are exposed to a higher dose than their normal-weight counterparts.

A study out of Israel has concluded heart attack survivors with an active sex life are better off than their less-active counterparts in the years following an MI, Reuters Health reported August 1.